Cancer Treatment Centers of America

We're available 24/7
(800) 615-3055

Chat online with us

Chat now

Other ways to contact us

Video
chat
(800) 615-3055

Have questions? Call (800) 615-3055 to speak to a cancer information specialist.
Or we can call you.

Radium-223 (Xofigo®)

Radium-223

Brand Name: Xofigo®

Radium-223 is a an alpha particle-emitting drug used to treat advanced prostate cancer, specifically in men whose cancer has spread (metastasized) to their bones after surgery or other treatments to lower testosterone.

Radium-223 is injected into a vein (intravenous) once a month. It works by using radioactive particles to mimic calcium and targeting cancer in the bones. The drug binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues.

The exact dose and schedule of carboplatin depends on your size, among other factors. Your doctor will determine the approach that is best for you.

The FDA approved radium-223 in May 2013 under its priority review program to bring drugs to market quickly. The program expedites approval for drugs that appear to:

  • Provide safe and effective treatment when no other satisfactory treatment exists, or
  • Offer significant improvement over exiting treatments

Radium-223 side effects

The FDA approved radium-223 in May 2013 under its priority review program to bring drugs to market quickly. The clinical trial of radium-223 involved 809 men with prostate cancer that had spread to their bones but not to other organs. Men who received the drug lived an average of 14 months compared to about 11 months for men who received a placebo injection.

The most common side effects in studies were

  • Nausea
  • Diarrhea
  • Vomiting
  • Swelling of the leg, ankle or foot

Please note that this is not a comprehensive list. Patients may experience additional effects not mentioned above.

At Cancer Treatment Centers of America® (CTCA), your team of cancer experts will explain the side effects of radium-223 with you in detail, as well as the side effects and expectations of all other medications planned as part of your individualized treatment plan.

Radium-223 for cancer treatment

Radium-223 is approved the FDA for the treatment of:

  • Prostate cancer that has spread (metastasized) to their bones after surgery or other treatments to lower testosterone

At Cancer Treatment Centers of America® (CTCA), our integrative approach to cancer treatment works to fight your disease on all fronts and ensures that you remain at the center of everything we do. We encourage participation from both you and your family to make certain you are comfortable with all decisions made regarding your treatment.

The information provided here is for educational purposes only. In no way should it be considered as offering medical advice. Cancer Treatment Centers of America assumes no responsibility for how this material is used. Please check with a physician if you suspect you are ill. Also note that while Cancer Treatment Centers of America frequently updates its contents, medical information changes rapidly. Therefore, some information may be out of date.

Your browser (Internet Explorer 7) is out of date. Learn how to update your browser.